BECKLEY FOUNDATION SCIENTIFIC PROGRAMME 2019 1 For the past 20 years the Beckley Foundation has been initiating groundbreaking research into psychedelics while also working towards the reform of global drug policies, led by the vision of its founder and director Amanda Feilding. THE TIME Psychedelics have the potential to create a revolutionary FOR PSYCHEDELIC paradigm shift in mental health. There is now a unique RESEARCH window of opportunity to accelerate research so that the therapeutic value of these compounds may be IS NOW recognised and used to their full potential. EXPANDING Amanda Feilding is committed to using this momentum THE FRONTIERS to further push the limits of scientific knowledge, with OF PSYCHEDELIC a wide spectrum of ongoing projects investigating KNOWLEDGE psilocybin, LSD, ayahuasca, DMT, 5MeO-DMT, cannabis and MDMA. PREPARING Our aim is to refine our understanding of how these FOR THE FUTURE compounds can be used to treat a wide range of different OF PSYCHEDELIC health conditions, and optimize the various ways they THERAPY can provide help to patients in need, and improve wellbeing and creativity in the healthy. Many thanks to our donors! The Beckley Foundation relies exclusively on the generosity of our supporters. Donations of any amount are greatly appreciated and help us develop and expand our science, policy and outreach programmes. Hold your phone camera up to the QR code to access our Scientific Brochure and support the work of the Foundation. To donate, please visit beckleyfoundation.org/donate 2 Table of Contents Why support us? ………………………………………………………………………………….4 Amanda Feilding and the Beckley Foundation………………………………….…..5 Selected Scientific Achievements...................………………………………….…..6 Spotlight on the Beckley/Imperial Research Programme………………….…..8 Beckley Foundation LSD Research Programme: ………………………………….10 Unravelling the potential of LSD microdosing…………………………........11 Understanding LSD’s underlying mechanisms of action……………......12 Beckley Foundation Psilocybin Research Programme…………………………14 Beckley Foundation Ayahuasca Research Programme…………………………15 Beckley Foundation Cannabis Research Programme:…………………………16 Insights from our Science Research Programme.………………………………...17 Selected Scientific Articles…………………………………………....................…… 19 Policy Programme.......................................……………………………................20 Recent coverage of Amanda Feilding in the media ……………………………..22 Beckley Foundation Scientific Advisory Board……………………………………..23 3 Why Support Us? Groundbreaking psychedelic therapies could be the start of a paradigm shift in the treatment of mental health. This is a truly exciting time for psychedelic research, and there is a desperate need to support it. Psychedelics can transform the way we understand and treat mental health conditions. We are facing an ever-worsening mental health epidemic. Everywhere, rates of anxiety, depression and addiction are on the rise, exerting a vast personal and economic toll. Psychiatry is largely ill-equipped to remedy this situation, and there is an urgent need for novel therapies and treatments. Psychedelic therapies are the perfect candidate for a breakthrough in mental health. Psychedelics have been shown to be well tolerated and highly effective medications in numerous scientific studies, with both immediate and long-lasting effects. Recent evidence from pre-clinical research is demonstrating the unique properties of psychedelics, with potential therapeutic applications that extend far beyond the field of psychiatry (e.g. inflammatory and neurodegenerative disorders). It is essential that more research is conducted into the underlying mechanisms and therapeutic applications of these highly promising compounds. The Beckley Foundation will continue playing a pioneering role in this area. 4 Amanda Feilding and the Beckley “Psychedelics are a key to unlock a deeper level of the psyche. They can transform the individual in ways that modern science is only just beginning to understand.” – Amanda Feilding psychoactive substances (cannabis, psilocybin, LSD, ayahuasca, DMT, 5MeO-DMT and MDMA) on brain function, subjective experience, and clinical symptoms. This pioneering research has led to a groundswell of interest in, and recognition of, the possible benefits that careful use of these extraordinary compounds can yield, and started demonstrating the great promise psychedelics hold in helping individuals with illnesses such as treatment-resistant depression and addiction. Bringing together a network of scientists, politicians and drug policy analysts, she was among the first to begin creating a scientific Amanda Feilding has been called the ‘hidden evidence-base to help reform global drug hand’ behind the renaissance of psychedelic policies, in order to better protect health, reduce science, and her contribution to global drug harms and economic costs, and uphold human policy reform has also been pivotal and widely rights. acknowledged. Amanda was first introduced to LSD in the mid-1960s, at the height of the first From 1998, she initiated and hosted a series of 11 wave of scientific research into psychedelics. Seminars in the House of Lords, discussing key policy issues and drawing attention to the then Impressed by its capacity to initiate mystical ignored topics of cannabis and psychedelics. states of consciousness and heighten creativity, These seminars, and the papers arising from she quickly recognised its transformative and them, were highly influential in changing therapeutic power. Inspired by her experiences, attitudes among thinkers and policy-makers Amanda began studying the mechanisms worldwide. underlying the effects of psychedelic substances and dedicated herself to exploring Through the Beckley Foundation, Amanda ways of harnessing their potential to enhance continues to bridge the divide between science wellbeing. and drug policy; her pioneering psychedelic research is providing the scientific evidence In 1998, Amanda set up the Beckley Foundation. upon which a case for drug policy reform can Since then, she has initiated much ground- be built. Such reform will, in turn, allow for breaking research and has contributed to further research on these currently prohibited over 50 scientific articles published in peer- substances to progress and hopefully result reviewed journals. Amanda has collaborated in their rescheduling and the availability of with leading scientists and institutions around psychedelic-assisted psychotherapy for those the world to design and direct a wide range of in need. scientific research investigating the effects of Amanda Feilding – Photo by Imogen Freeland 5 Selected Scientific Achievements 1970s: AF writes Blood & Consciousness and delivers exhibitions around the topic of consciousness and its changing states at the ICA in London and PSI in New York, etc. 1998: AF collaborates with Prof Franz Vollenweider on a study investigating psilocybin’s effects on changes in cerebral circulation using PET. 2005: AF initiates a research collaboration with Prof David Nutt at the University of Bristol, with the aim of investigating the effects of cannabis, LSD and psilocybin and cannabis on brain function, using brain imaging. 2005-2007: AF sets up a collaboration with Berkeley, California, which gained the first ethical approval for a brain imaging study with LSD in humans. 2008: AF establishes the Beckley/Imperial Research Programme with Prof David Nutt and herself as co- directors, and appoint Dr Robin Carhart-Harris as PI (see p9). 2012: The Beckley/Imperial Research Programme publishes the first neuroimaging study of the neural correlates of the psychedelic state induced by psilocybin (see p10), and carries out the first brain imaging study on individuals under the influence of MDMA. 2015: AF’s collaborative research with UCL on the effects of two different strains of cannabis is featured in the Channel 4 documentary Drugs Live: The Cannabis Trial. 2016: The Beckley/Imperial Research Programme publishes ground-breaking results on psilocybin- assisted therapy for treatment resistant depression (see p10). The Beckley/Imperial Research Programme publishes the first images of the human brain on LSD (see p11). AF’s collaboration with Johns Hopkins produces first scientific evidence for the potential of psilocybin- assisted therapy for smoking cessation (see p17). 2017-2018: AF sets up the Beckley/Brazil and the Beckley/Maastricht Psychedelic Research Programmes, investigating the potential of LSD. Courtesy of Greg Dunn 6 Spotlight on the Beckley/Imperial Research Programme The Beckley/Imperial Research Programme Harris to join the Beckley/Imperial has been a highly productive partnership Psychedelic Research Programme in 2009 as between Amanda Feilding and Prof David Principal Investigator and Beckley Research Nutt, co-founders and directors of the Fellow. Following up on the success of the Programme, and Dr Robin Carhart-Harris, Beckley/Imperial psilocybin for treatment principal investigator. The collaboration resistant depression study, he is now leading began in 2005, when Amanda approached a larger phase II double-blind randomized David about forming a partnership to controlled clinical trial, comparing changes investigate the effects of psychedelics in depression and imaging outcomes after and cannabis on brain function. Many new a single dose of psilocybin versus six weeks scientists have since joined the team. of an SSRI treatment for major depressive The programme has carried out pioneering disorder.